Pifer Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 03-12-2024
- Paid Up Capital ₹ 0.42 M
as on 03-12-2024
- Company Age 30 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.11 M
as on 03-12-2024
- Satisfied Charges ₹ 2.20 M
as on 03-12-2024
- Revenue %
(FY 2020)
- Profit -1.61%
(FY 2020)
- Ebitda
- Net Worth -0.68%
(FY 2020)
- Total Assets -0.09%
(FY 2020)
About Pifer Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.42 M.
The company currently has active open charges totaling ₹4.11 M. The company has closed loans amounting to ₹2.20 M, as per Ministry of Corporate Affairs (MCA) records.
Munish Salwan and Mithun Salwan serve as directors at the Company.
- CIN/LLPIN
U24232PB1994PTC014446
- Company No.
014446
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Apr 1994
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationPunjab, Punjab
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Pifer Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Munish Salwan  | Director | 18-Apr-1994 | Current |
| Mithun Salwan | Director | 30-Nov-2003 | Current |
Financial Performance of Pifer Pharmaceuticals.
Pifer Pharmaceuticals Pvt Ltd, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 1.61% decrease in profit. The company's net worth dipped by a decrease of 0.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Pifer Pharmaceuticals?
In 2019, Pifer Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Oriental Bank Of Commerce Creation Date: 30 Dec 2004 | ₹0.50 M | Open |
Oriental Bank Of Commerce Creation Date: 30 Dec 2004 | ₹0.50 M | Open |
Punjab National Bank Creation Date: 20 May 2002 | ₹1.00 M | Open |
How Many Employees Work at Pifer Pharmaceuticals?
Unlock and access historical data on people associated with Pifer Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pifer Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pifer Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
